Angelalign Technology (SEHK:6699) Lifts Earnings Guidance, Is The Premium Already Priced In?

Angelalign Technology (SEHK:6699) drew investor attention after issuing new earnings guidance for the six months to 30 June 2026, highlighting higher clear aligner volumes, revenue and net profit compared with the same period in 2025.

See our latest analysis for Angelalign Technology.

Angelalign Technology’s latest guidance comes after a strong run in the stock, with a 30-day share price return of 28.07% and year to date share price return of 54.35%. However, the 5-year total shareholder return is still down 73.05%, showing that recent momentum contrasts with a weaker long term record.

If this earnings update has you thinking more broadly about opportunities in medical and dental technology, it can be useful to scan other healthcare AI names that are gaining attention through the Simply Wall St screener, such as the 130 healthcare AI stocks.

Given Angelalign Technology’s sharp rebound after years of weaker long term returns, it is fair to ask how much of this move reflects improving earnings guidance and how much comes from changing sentiment around the stock’s story.

Preferred P/E of 72x for Angelalign Technology: Is it justified?

Angelalign Technology is currently trading on a P/E of 72x, which sits well above its own estimated fair P/E of 21x and its sector peers. That raises a clear question for investors about how much optimism is already reflected in the HK$94 share price.

The P/E ratio compares the current share price with earnings per share. For a healthcare equipment company like Angelalign Technology, it is often used to gauge how much the market is willing to pay today for each unit of current earnings, especially when growth expectations are in focus.

In this case, the 72x P/E is described as expensive compared with the estimated fair P/E of 21x, and also relative to both the Hong Kong Medical Equipment industry average of 15.2x and a peer average of 28.6x. The gap suggests the market is assigning a sizeable premium that may be hard to justify if earnings or sentiment fall short of expectations, and it also shows a level that the valuation could potentially move toward if that premium narrows.

Explore the SWS fair ratio for Angelalign Technology

Result: Price-to-earnings of 72x (OVERVALUED)

However, Angelalign Technology’s premium P/E could come under pressure if execution on earnings guidance disappoints or if demand for clear aligners softens.

Find out about the key risks to this Angelalign Technology narrative.

Another view on Angelalign Technology using cash flows

While the P/E of 72x suggests Angelalign Technology is priced richly, the SWS DCF model points to a fair value of HK$81.52 against the current HK$94 share price. That implies the stock screens as overvalued on cash flows as well. Which signal do you weigh more heavily?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Angelalign Technology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 262 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Angelalign Technology clearly mixed, this is a good moment to look through the details yourself and decide how convincing the story feels. To weigh both the concerns and the potential upside in one place, take a closer look at the 2 key rewards and 2 important warning signs.

Looking for more Angelalign Technology investment ideas?

If Angelalign Technology has sharpened your focus on where to put your money next, do not sit on the sidelines while other opportunities move ahead.

• Target potential mispricing by scanning companies that combine quality fundamentals with value using the 262 high quality undervalued stocks.
• Strengthen your defensive side by reviewing stocks with robust finances through the solid balance sheet and fundamentals stocks screener (423 results).
• Hunt for lesser known opportunities that still meet strict quality checks with the screener containing 555 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com